01.03.2012 08:05 Uhr, Quelle: Wallstreet online

Bavarian Nordic Submits a Marketing Application for its Smallpox Vaccine to the European Medicines Agency

KVISTGAARD, Denmark, March 1, 2012 - Bavarian Nordic A/S (OMX: BAVA) announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its smallpox vaccine (IMVAMUNE(®)) that will be …

Weiterlesen bei Wallstreet online